Overview
- Spyre Therapeutics, which reported Phase 2 results Monday, saw its shares jump roughly 30% to a multi‑year high.
- SPY001 met the study’s main goal by cutting tissue‑level inflammation at 12 weeks, with 40% of patients in clinical remission and 51% showing endoscopic improvement in this colon inflammation disease.
- Safety in the 12‑week induction period included six treatment‑emergent events, one serious event labeled unrelated to the drug, and back pain as the most common side effect in two patients.
- Recruitment for SKYLINE Part A has closed and Part B enrollment is open across monotherapy and combo cohorts, with more readouts expected in mid‑2026 and Q3 2026 and Part B induction data planned for 2027.
- Following Monday’s results, the company launched a $300 million share offering with a $45 million overallotment option, as it positions SPY001 against Takeda’s Entyvio and touts cross‑trial comparisons with J&J’s VEGA.